Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The beta 1 hyperselectivity in beta-blocker treatment

J M Cruickshank1

  • 1Royal Brompton National Heart and Lung Hospital, London, England.

Journal of Cardiovascular Pharmacology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transversely excited atmospheric CO(2) laser radar with heterodyne detection.

Applied optics·2010
Same author

Are we misunderstanding beta-blockers.

International journal of cardiology·2007
Same author

New guidelines on hypertension.

Lancet (London, England)·2006
Same author

The hydration structure of guanidinium and thiocyanate ions: implications for protein stability in aqueous solution.

Proceedings of the National Academy of Sciences of the United States of America·2003
Same author

Renoprotection with antihypertensive agents.

Lancet (London, England)·2002
Same author

Beta-adrenergic blocking drugs in the treatment of hypertension.

Blood pressure·2002

Beta-blockers effectively prevent cardiovascular events like myocardial infarction and stroke, particularly in high-risk patients. These drugs reduce cardiac workload and improve outcomes in conditions such as hypertension and angina.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease (CHD) is a leading cause of mortality in industrialized nations.
  • CHD risk is elevated with co-existing hypertension and lipid abnormalities.
  • Beta-blockers are indicated for myocardial infarction (MI) prevention in high-risk individuals.

Purpose of the Study:

  • To review the evidence supporting beta-blocker use in cardiovascular disease prevention.
  • To highlight the mechanisms of action and clinical trial data for beta-blockade.
  • To discuss the evolution and benefits of beta-blocker therapy.

Main Methods:

  • Review of clinical trial data on beta-blocker efficacy.
  • Analysis of mechanisms including reduced myocardial oxygen demand and endothelial shear stress.

Related Experiment Videos

  • Comparison of early nonselective and modern selective beta-blockers.

    • Main Results:

    • Beta-blockade significantly reduces stroke incidence in hypertensive patients.
    • MI incidence is reduced by approximately 15% in younger hypertensive patients.
    • Secondary prevention post-MI shows 15-30% reduction in cardiovascular events.
    • Benefits observed in angina, hypertrophic cardiomyopathy, and heart failure.

    Conclusions:

    • Beta-blockers are effective in preventing cardiovascular end points.
    • Beta-1 selective blockade is key to cardiovascular benefits and improved quality of life.
    • Beta-blockers offer cardioprotection, endothelial protection, and atheroma prevention.